PCM
CHRS icon

Pyrrho Capital Management’s Coherus Oncology CHRS Stock Holding History

Pyrrho Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-27,133
Closed -$544K – 21
2015
Q3 		$544K Buy
+27,133
New +$826K 0.47% 38

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Pyrrho Capital Management's CHRS Position: Q4 2015 in Review

Pyrrho Capital Management sold out of Coherus Oncology (CHRS) in Q4 2015, closing a stake of 27,133 shares — an estimated $544K sold.

Pyrrho Capital Management first reported a position in CHRS in Q3 2015 and held it in 1 quarter. The position peaked at $544K in Q3 2015. 77 funds tracked by Wall St. Rank hold CHRS as of Q4 2015.

  • Pyrrho Capital Management reported no remaining Coherus Oncology position as of Q4 2015 after selling out during the quarter.
  • Pyrrho Capital Management sold 27,133 Coherus Oncology shares in Q4 2015, an estimated $544K.
  • Pyrrho Capital Management first reported a position in Coherus Oncology in Q3 2015 and held it in 1 quarter.
  • Pyrrho Capital Management's Coherus Oncology position peaked at $544K in Q3 2015.
  • 77 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2015.

Based on Pyrrho Capital Management's 13F filing for Q4 2015, filed 10 Feb 2016.